| Bioactivity | Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2. | ||||||||||||
| Invitro | Cancer-Targeting Compound 1 is useful for the research of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus[1]. | ||||||||||||
| Name | Cancer-Targeting Compound 1 | ||||||||||||
| CAS | 1007581-62-5 | ||||||||||||
| Formula | C15H13N3O2S | ||||||||||||
| Molar Mass | 299.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Thomas, Joseph, et al. OXAZOLIDONE DERIVATIVES AS PR MODULATORS. WO 2008021331 A2. |
Cancer-Targeting Compound 1
CAS: 1007581-62-5 F: C15H13N3O2S W: 299.35
Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.